Register entry

BSP Pharmaceuticals SpA

Registered sites
1
Drug products
39
Live patents
0
Countries
1
Base
Italy
Authorisation

Registered operations

What the FDA has registered these sites to do. This is the regulatory record, not a marketing claim.

Analytical testingActive ingredient (API) manufactureFinished drug manufacture
Sites

Facilities

1
SiteLocationOperationsFEI
BSP Pharmaceuticals SpALatina Scalo (LT)ItalyAnalytical testing, Active ingredient (API) manufacture, Finished drug manufacture3007255826
Catalogue

Marketed products

39

Showing 39 of 39.

BrandGeneric nameFormCategory
-Bendamustine HCI InjectionINJECTION, SOLUTIONDRUG FOR FURTHER PROCESSING
-Bendamustine HCI InjectionINJECTION, SOLUTIONDRUG FOR FURTHER PROCESSING
-Bortezomib 3.5mg/vialINJECTION, POWDER, LYOPHILIZED, FOR SOLUTIONDRUG FOR FURTHER PROCESSING
-Denileukin diftitox lyo 300 mcg/vial CITINJECTIONDRUG FOR FURTHER PROCESSING
Halaveneribulin mesylateINJECTIONNDA
-Loncastuximab tesirineINJECTION, POWDER, LYOPHILIZED, FOR SOLUTIONDRUG FOR FURTHER PROCESSING
-Mirikizumab Inj 300 mg/15 mL Vial ReformINJECTIONDRUG FOR FURTHER PROCESSING
-Mirikizumab Inj 300 mg/15mL VialINJECTIONDRUG FOR FURTHER PROCESSING
-Multiple-Dose Tirzepatide InjectionINJECTION, SOLUTIONDRUG FOR FURTHER PROCESSING
-Multiple-Dose Tirzepatide InjectionINJECTION, SOLUTIONDRUG FOR FURTHER PROCESSING
-Multiple-Dose Tirzepatide InjectionINJECTION, SOLUTIONDRUG FOR FURTHER PROCESSING
-Multiple-Dose Tirzepatide InjectionINJECTION, SOLUTIONDRUG FOR FURTHER PROCESSING
-Multiple-Dose Tirzepatide InjectionINJECTION, SOLUTIONDRUG FOR FURTHER PROCESSING
-Multiple-Dose Tirzepatide InjectionINJECTION, SOLUTIONDRUG FOR FURTHER PROCESSING
-Patritumab deruxtecanINJECTION, POWDER, LYOPHILIZED, FOR SOLUTIONDRUG FOR FURTHER PROCESSING
-Pemetrexed disodium heptahydratePOWDER, FOR SOLUTIONDRUG FOR FURTHER PROCESSING
-Pemetrexed disodium heptahydratePOWDER, FOR SOLUTIONDRUG FOR FURTHER PROCESSING
-Pivekimab sunirine drug product (DP)INJECTION, POWDER, LYOPHILIZED, FOR SOLUTIONDRUG FOR FURTHER PROCESSING
-Polatuzumab Vedotin lyophilized vials 140 mgINJECTION, POWDER, LYOPHILIZED, FOR SOLUTIONDRUG FOR FURTHER PROCESSING
-Polatuzumab Vedotin lyophilized vials 30 mgINJECTION, POWDER, LYOPHILIZED, FOR SOLUTIONDRUG FOR FURTHER PROCESSING
-TAR-200TABLETDRUG FOR FURTHER PROCESSING
-Telisotuzumab vedotinINJECTIONDRUG FOR FURTHER PROCESSING
-Trastuzumab Emtansine drug product 100 mgINJECTION, POWDER, LYOPHILIZED, FOR SOLUTIONDRUG FOR FURTHER PROCESSING
-Trastuzumab Emtansine drug product 160 mgINJECTION, POWDER, LYOPHILIZED, FOR SOLUTIONDRUG FOR FURTHER PROCESSING
-cedazuridine and decitabineTABLET, FILM COATEDDRUG FOR FURTHER PROCESSING
-enfortumab vedotin-ejfv for injectionINJECTIONDRUG FOR FURTHER PROCESSING
-enfortumab vedotin-ejfv for injectionINJECTIONDRUG FOR FURTHER PROCESSING
-mirvetuximab soravtansine gynxINJECTIONDRUG FOR FURTHER PROCESSING
-pembrolizumab and berahyaluronidase alfaINJECTION, SOLUTIONDRUG FOR FURTHER PROCESSING
-pembrolizumab and berahyaluronidase alfaINJECTION, SOLUTIONDRUG FOR FURTHER PROCESSING
-sacituzumab govitecanINJECTION, POWDER, LYOPHILIZED, FOR SOLUTIONDRUG FOR FURTHER PROCESSING
-telisotuzumab vedotinINJECTIONDRUG FOR FURTHER PROCESSING
-tirzepatideINJECTION, SOLUTIONDRUG FOR FURTHER PROCESSING
-tirzepatideINJECTION, SOLUTIONDRUG FOR FURTHER PROCESSING
-tirzepatideINJECTION, SOLUTIONDRUG FOR FURTHER PROCESSING
-tirzepatideINJECTION, SOLUTIONDRUG FOR FURTHER PROCESSING
-tirzepatideINJECTION, SOLUTIONDRUG FOR FURTHER PROCESSING
-tirzepatideINJECTION, SOLUTIONDRUG FOR FURTHER PROCESSING
-vestronidase alfa-vjbkINJECTIONDRUG FOR FURTHER PROCESSING
Provenance

Facility and operations data from the FDA Drug Establishments Current Registration Site. Product data from the openFDA National Drug Code Directory. Patent and exclusivity data from the FDA Orange Book. Shortage data from the FDA drug shortage database. Contact details the FDA publishes for registered establishments are deliberately not reproduced here. This entry is compiled from public records and has not been claimed by the company.